Healthcare provider profile · identity verified

Thomas W Cohee, MD

Allopathic & Osteopathic Physicians|Family Medicine · WEST POINT, NE · NPI 1306932579

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Thomas W Cohee, MD received $31.09 in general payments during 2025 across 1 reported records.

ABBVIE INC. accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 2 associated products.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$31.09

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
ABBVIE INC.	Unresolved — no canonical attribution shown	$31.09	100.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$31.09	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
QULIPTA Normalized: qulipta	Drug	ABBVIE INC.	$31.09	1	2025
Source payment records 2025-06-10 · ABBVIE INC. · $31.09 · Open Payments source
UBRELVY Normalized: ubrelvy	Drug	ABBVIE INC.	$31.09	1	2025
Source payment records 2025-06-10 · ABBVIE INC. · $31.09 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	382	98
Arexvy	Rsvpref3 Antigen/As01e/Pf	246	246
Gabapentin	Gabapentin	238	54
Lisinopril	Lisinopril	235	66
Furosemide	Furosemide	224	48
Eliquis	Apixaban	220	33
Levothyroxine Sodium	Levothyroxine Sodium	215	50
Metoprolol Succinate	Metoprolol Succinate	202	49
Omeprazole	Omeprazole	195	50
Shingrix	Varicella-Zoster Ge/As01b/Pf	175	124
Amlodipine Besylate	Amlodipine Besylate	174	44
Metformin Hcl	Metformin Hcl	173	40
Simvastatin	Simvastatin	155	33
Losartan Potassium	Losartan Potassium	127	31
Escitalopram Oxalate	Escitalopram Oxalate	126	31
Metoprolol Tartrate	Metoprolol Tartrate	125	18
Tamsulosin Hcl	Tamsulosin Hcl	115	25
Potassium Chloride	Potassium Chloride	106	26
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	98	22
Sertraline Hcl	Sertraline Hcl	91	18
Tramadol Hcl	Tramadol Hcl	88	28
Meloxicam	Meloxicam	83	21
Albuterol Sulfate Hfa	Albuterol Sulfate	74	23
Glipizide Er	Glipizide	73	18
Hydrochlorothiazide	Hydrochlorothiazide	73	21
Trulicity	Dulaglutide	68	suppressed
Warfarin Sodium	Warfarin Sodium	66	suppressed
Baclofen	Baclofen	65	11
Prednisone	Prednisone	64	41
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	62	15
Clopidogrel	Clopidogrel Bisulfate	60	12
Pantoprazole Sodium	Pantoprazole Sodium	58	22
Alprazolam	Alprazolam	53	16
Mounjaro	Tirzepatide	52	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	52	12
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	51	12
Cefdinir	Cefdinir	48	37
Duloxetine Hcl	Duloxetine Hcl	48	11
Allopurinol	Allopurinol	47	15
Boostrix Tdap	Diphth,pertuss(Acell),tet Vac	45	45
Pioglitazone Hcl	Pioglitazone Hcl	45	12
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	40	suppressed
Topiramate	Topiramate	40	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	39	suppressed
Trazodone Hcl	Trazodone Hcl	39	14
Carvedilol	Carvedilol	38	suppressed
Lorazepam	Lorazepam	38	suppressed
Xarelto	Rivaroxaban	38	suppressed
Pravastatin Sodium	Pravastatin Sodium	37	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	36	suppressed
Montelukast Sodium	Montelukast Sodium	34	suppressed
Alendronate Sodium	Alendronate Sodium	33	suppressed
Entresto	Sacubitril/Valsartan	33	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	33	19
Zolpidem Tartrate	Zolpidem Tartrate	32	13
Amitriptyline Hcl	Amitriptyline Hcl	31	suppressed
Azithromycin	Azithromycin	31	27
Pregabalin	Pregabalin	31	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	31	27
Spironolactone	Spironolactone	30	suppressed
Fenofibrate	Fenofibrate	29	suppressed
Fluticasone Propionate	Fluticasone Propionate	29	14
Doxycycline Hyclate	Doxycycline Hyclate	26	19
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	26	14
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	25	11
Jardiance	Empagliflozin	25	suppressed
Ventolin Hfa	Albuterol Sulfate	25	15
Donepezil Hcl	Donepezil Hcl	24	suppressed
Cephalexin	Cephalexin	23	20
Ropinirole Hcl	Ropinirole Hcl	23	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	23	suppressed
Fentanyl	Fentanyl	22	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	22	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	21	19
Ezetimibe	Ezetimibe	21	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	21	suppressed
Aimovig Autoinjector	Erenumab-Aooe	20	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	20	suppressed
Oxycodone Hcl	Oxycodone Hcl	20	suppressed
Propranolol Hcl	Propranolol Hcl	20	suppressed
Buspirone Hcl	Buspirone Hcl	19	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	19	suppressed
Paroxetine Hcl	Paroxetine Hcl	19	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	18	suppressed
Nystatin	Nystatin	18	suppressed
Benazepril Hcl	Benazepril Hcl	17	suppressed
Bumetanide	Bumetanide	17	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	17	suppressed
Famotidine	Famotidine	17	suppressed
Ketoconazole	Ketoconazole	17	suppressed
Repatha Sureclick	Evolocumab	17	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	17	suppressed
Digoxin	Digoxin	16	suppressed
Enalapril Maleate	Enalapril Maleate	16	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	16	suppressed
Metformin Hcl Er	Metformin Hcl	16	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	16	suppressed
Spiriva Respimat	Tiotropium Bromide	16	suppressed
Verapamil Er	Verapamil Hcl	16	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	15	suppressed
Levemir Flexpen	Insulin Detemir	15	suppressed
Naratriptan Hcl	Naratriptan Hcl	15	suppressed
Novolog Flexpen	Insulin Aspart	15	suppressed
Ondansetron Odt	Ondansetron	15	11
Acyclovir	Acyclovir	14	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	14	suppressed
Diclofenac Sodium	Diclofenac Sodium	14	suppressed
Estradiol	Estradiol	14	suppressed
Ramipril	Ramipril	14	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	13	suppressed
Chlorthalidone	Chlorthalidone	13	suppressed
Cholestyramine Light	Cholestyramine	13	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	13	suppressed
Mirtazapine	Mirtazapine	13	suppressed
Myrbetriq	Mirabegron	13	suppressed
Primidone	Primidone	13	suppressed
Tresiba Flextouch U-100	Insulin Degludec	13	suppressed
Breo Ellipta	Fluticasone/Vilanterol	12	suppressed
Clomipramine Hcl	Clomipramine Hcl	12	suppressed
Diazepam	Diazepam	12	suppressed
Estradiol (Once Weekly)	Estradiol	12	suppressed
Glimepiride	Glimepiride	12	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	12	suppressed
Praluent Pen	Alirocumab	12	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	12	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	11	suppressed
Amoxicillin	Amoxicillin	11	11
Gemtesa	Vibegron	11	suppressed
Ibuprofen	Ibuprofen	11	suppressed
Triazolam	Triazolam	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$31.09 · 1 records	ABBVIE INC.	QULIPTA, UBRELVY	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error